 The purpose of this Phase 1 study is to evaluate the safety and potential efficacy of Gene Mediated Cytotoxic Immunotherapy for pancreatic cancer. The approach uses an adenoviral vector disabled virus engineered to express the Herpes thymidine kinase gene AdV-tk, followed by an antiherpetic prodrug, valacyclovir. 